profit from every $100 of sales.
$0$100
Estrella Immunopharma
$0.51+36.93% today
-82.5% in 1 year
1-year low $0.311-year high $2.93
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Estrella Immunopharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$13.1 million of profit last year.
SalesProfit
Estrella Immunopharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Estrella Immunopharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Estrella Immunopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -2 | -11 | -7 | -13 | |
| -2 | -11 | -7 | -13 | |
| -2 | -11 | -7 | -13 | |
| -0.05 | -0.32 | -0.27 | -0.35 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 5 | 3 | 4 | 3 |
| Cash | 4 | 2 | 4 | 1 |
| Total debt | – | – | – | – |
| Total liabilities | 6 | 15 | 0 | 14 |
| -1 | -12 | 4 | -10 | |
| 35 | 35 | 27 | 37 | |
| – | – | -135.1% | – | |
| 162.1% | 94.7% | -171.1% | 126.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | -1 | -16 | -2 | |
| – | – | – | – | |
| -1 | -1 | -16 | -2 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 0 | |
| 0 | 0 | 1 | 1 |
Valuation
- –
- –
- –
- -9.3×
- –
- –
- –
- -8.0%
- -58.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 249.4%
- -1,210.4%
- 167.9%
- -362.3%
- 249.4%
- –
Growth
- –
- –
- +76.6%
- –
- +58.4%
Financial health
- -0.1×
- 0.00
- 0.0%
- –
- 0.24
- 0.24
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Bottom 14%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.05 | -0.08 | +40.5% |
| Mar 18, 2026 | -0.02 | -0.18 | +91.0% |
| Nov 12, 2025 | -0.13 | -0.19 | +30.3% |
| Aug 11, 2025 | -0.15 | -0.07 | −114.3% |
| May 14, 2025 | -0.06 | -0.11 | +45.5% |
| Feb 15, 2025 | -0.03 | -0.12 | +76.1% |
| Nov 14, 2024 | -0.09 | – | – |
| Sep 27, 2024 | -0.13 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
16No pass
Benjamin Graham
32No pass
Philip Fisher
30No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
35No pass
Terry Smith
28No pass
Questions about Estrella Immunopharma
Is Estrella Immunopharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Estrella Immunopharma AI analysis
What does Estrella Immunopharma do?
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. It is in Biotechnology.
Does Estrella Immunopharma pay a dividend?
No. Estrella Immunopharma does not pay a dividend at the moment; in 2025 it returned $29,462 to shareholders by buying back its own shares.
Is Estrella Immunopharma stock halal?
Yes. Estrella Immunopharma passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has Estrella Immunopharma stock done over the past year?
Down 82.5% over the past twelve months, to $0.51. It traded between $0.31 and $2.93 and is 82.5% below its high.
Who are Estrella Immunopharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Estrella Immunopharma's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.